eFFECTOR Therapeutics Inc

eFFECTOR Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of a new class oncology drugs known as selective translation regulator inhibitors (STRIs). Its STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase 1/2 (MNK 1/2). The company was founded by Kevan Shokat, Davide Ruggero, and Siegfried Reich on May 1, 2012 and is headquartered in Solana Beach, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Athersys

Cano Health

Genius Group Ltd

Canoo

Pieris Pharma

T2 Biosystems

Penny stocks, often priced under $1, have long been the allure for many investors seeking high-risk, high-reward opportunities. These stocks, typically from smaller companies, offer the tantalizing possibility of significant returns.

7 Best Penny Stocks To Buy Under $1 in 2023: Big Risk, Big Return?

Are you looking for the best penny stocks to buy? You're not alone; many traders are showing a renewed interest in this exciting market.

Best Penny Stocks To Buy Under $1.25? 3 To Watch Now

Positive data update from Phase 2 expansion cohort evaluating zotatifin combined with fulvestrant and abemaciclib (ZFA triplet) in estrogen receptor-positive (ER+) metastatic breast cancer (mBC) presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023

eFFECTOR Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Akebia Therapeutics

Terawulf

There are so many new traders and investors entering the stock market today. But if you're brand new, you might not have a lot of money to invest or don't want to risk a whole lot while you're learning how to trade.

Best Stocks For Beginners with Little Money: How To Trade Penny Stocks

eFFECTOR Closes Second Registered Direct Offering Priced At-The-Market Under Nasdaq Rules eFFECTOR Closes Second Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

eFFECTOR Therapeutics Raises a Total of $16.2 Million in Gross Proceeds from Two Recent Registered Direct Offerings

Freight Technologies Inc

Hyzon Motors

Seres Therapeutics

TuSimple Holdings

Are you searching for some of the best penny stocks to buy now? I'm sure that if you're reading this article, that's something at the top of your mind.

Best Penny Stocks To Buy? 5 With Big News This Week

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase and sale of an aggregate of 7,764,445 shares of its common stock (or common stock equivalents in lieu thereof), at a purchase price of $1.125 per share (or common stock equivalent in lieu thereof), in a registered direct offering priced at-the-market under Nasdaq rules. The Company has also agreed to issue in a concurrent private placement unregistered warrants to purchase up to an aggregate of 7,764,445 shares of common stock. The unregistered warrants will have an exercise price of $1.00 per share, will be immediately exercisable upon issuance, and will expire five and one-half years from the date of issuance. The closing of the offering is expected to occur on or about June 8, 2023, subject to the satisfaction of customary closing conditions.

eFFECTOR Therapeutics Announces $8.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Ads-Tec Energy PLC

Applied Blockchain Inc

Context Therapeutics LLC

Minerva Neurosciences

Nasdaq ETF marked first six-week rally since Jan 2020. These stocks gained more than 100% during this time frame.

Nasdaq ETF's First Six-week Rally Since Jan 2020: Stock Winners

Hookipa Pharma Inc

Taboola

This week has seen the stock market flip-flop, including the volatile world of penny stocks. Investors, especially those interested in high-risk, high-reward low-priced stocks, are attentively tracking the developments in Washington.

Stock Market Today: New Penny Stocks Trends & 3 To Watch This Week

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, announced today that it has closed its previously announced registered direct offering for the purchase and sale of an aggregate of 11,450,382 shares of its common stock (or common stock equivalents in lieu thereof), at a purchase price of $0.655 per share (or common stock equivalent in lieu thereof), priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company issued unregistered warrants to purchase up to an aggregate of 11,450,382 shares of common stock with an exercise price of $0.53 per share which are immediately exercisable for a period of five and one-half years following issuance.

eFFECTOR Therapeutics Announces Closing of $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Lumen Technologies

D-Wave Quantum Inc

Penny stocks, known for their low market price and high growth potential, are an exciting segment of the financial market, particularly in sectors like technology. These low-cost shares can provide significant returns if chosen wisely, making it imperative for investors to possess tools and techniques for evaluating market sentiment.

Evaluating Market Sentiment With Penny Stocks: Top Tools

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 26, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase and sale of an aggregate of 11,450,382 shares of its common stock (or common stock equivalents in lieu thereof), at a purchase price of $0.655 per share (or common stock equivalent in lieu thereof), in a registered direct offering priced at-the-market under Nasdaq rules. The Company has also agreed to issue in a concurrent private placement unregistered warrants to purchase up to an aggregate of 11,450,382 shares of common stock. The unregistered warrants will have an exercise price of $0.53 per share, will be immediately exercisable upon issuance, and will expire five and one-half years from the date of issuance. The closing of the offering is expected to occur on or about May 31, 2023, subject to the satisfaction of customary closing conditions.

eFFECTOR Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

EFFECTOR Therapeutics (NASDAQ: EFTR ) stock is taking off on Friday after the company reported positive data from a Phase 2 clinical trial. This includes interim data from its expansion cohort evaluating zotatifin combined with fulvestrant and abemaciclib.

Why Is eFFECTOR Therapeutics (EFTR) Stock Up 75% Today?

Partial responses observed in 5 of 19 (26%) evaluable patients treated with zotatifin 0.07 mg/kg combined with fulvestrant and abemaciclib (ZFA triplet) in heavily pretreated population Partial response observed in 1 of 3 (33%) patients treated with zotatifin 0.1 mg/kg combined with fulvestrant (ZF doublet) Both combinations were generally well tolerated with large majority of adverse events Grade 1 or 2 Company will host a virtual investor call on June 4, 2023, to discuss the data and clinical progress

eFFECTOR Therapeutics Reports Positive Data Updates from Phase 2 Expansion Cohorts Evaluating Zotatifin in Patients with ER+ Metastatic Breast Cancer at the ASCO 2023 Annual Meeting

Alzamend Neuro

Synlogic

Turning $1,000 into $10,000 in a year in the stock market is undoubtedly a lofty goal. Make no bones about it, it's not particularly likely to happen.

3 Penny Stocks That Could Turn $1,000 into $10,000 in a Year

Updated data from two fully enrolled Phase 2 expansion cohorts testing zotatifin-based combinations in estrogen receptor-positive (ER+) Metastatic Breast Cancer to be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023 on June 4, 2023

eFFECTOR Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that the Company will present and host 1x1 meetings at the JMP Securities Life Sciences Conference taking place May 15-16, 2023 in New York, NY.

eFFECTOR Therapeutics to Present at JMP Securities Life Sciences Conference

SOLANA BEACH, Calif. and REDWOOD CITY, Calif.

eFFECTOR to Present Updated Clinical Data from Phase 2 Expansion Cohorts for Zotatifin in Patients with ER+ Metastatic Breast Cancer at ASCO 2023 Annual Meeting

The Company's eIF4A inhibitor, zotatifin, will be tested in specific genomically-defined subgroups, including standard risk patients as well as high-risk patients carrying specific markers predictive of relapse The Company's eIF4A inhibitor, zotatifin, will be tested in specific genomically-defined subgroups, including standard risk patients as well as high-risk patients carrying specific markers predictive of relapse

eFFECTOR Therapeutics to Collaborate with Stanford Medicine on Investigator-Initiated Randomized Phase 2 Study in Patients with ER+ Breast Cancer

Zotatifin continued to demonstrate favorable activity and tolerability, including two previously reported confirmed partial responses (PRs) among seven heavily pretreated subjects who received zotatifin, fulvestrant and abemaciclib (ECBF+A)

eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Results presented at 30th Conference on Retroviruses and Opportunistic Infections (CROI) Results presented at 30th Conference on Retroviruses and Opportunistic Infections (CROI)

eFFECTOR Therapeutics Announces Positive Top-Line Results from Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, announced that the Company will present and host 1x1 meetings at the 2023 BIO CEO & Investor Conference from February 6-9, 2023 in New York City, NY.

eFFECTOR Therapeutics to Present at 2023 BIO CEO & Investor Conference

The stock price of eFFECTOR Therapeutics (EFTR) increased by 13.02% after hours in the most recent trading session. This is why.

EFTRWhy The eFFECTOR Therapeutics Stock Increased 13.02% After Hours (EFTR)

Zotatifin continues to show favorable activity profile, including two confirmed partial responses (PR) among seven heavily pretreated subjects who received zotatifin, fulvestrant and abemaciclib (ECBF+A), with good tolerability

eFFECTOR Therapeutics Provides Positive Clinical Data Update for Zotatifin and General Corporate Update

- Key executive appointments: Douglas Warner, M.D., as CMO & Mayank Gandhi, M.D., as CBO –

eFFECTOR Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

News for eFFECTOR Therapeutics Inc Stock (EFTR)